Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Megan C. Madonna has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In vivo imaging of metabolic heterogeneity across three endpoints relevant to aggressive breast cancer

    by Victoria W D’AGostino, Michelle Kwan, Adelle Yong, Kira Grossman, Enakshi D Sunassee, Megan C Madonna, Matthew Hirschey, Gregory M Palmer, Nirmala Ramanujam

    Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis and a high likelihood of recurrence. Residual disease after therapy is a key predictor of recurrence, often driven by intratumoral metabolic heterogeneity. Accumulating evidence indicates that tumors are able to shift between glycolysis and oxidative metabolism and alter nutrient preferences to sustain growth and resist therapy. We have developed a in vivo microscope that enables near-simultaneous measurements of fluorescent metabolic surrogates of glucose, fatty acids, and oxidative phosphorylation through a combination of spectral separation and sequential delivery schemes. Widefield imaging with uniform illumination across the entire tumor landscape (5 mm × 5 mm) informs on the spatial distribution of these metabolic probes. We used this technology to investigate metabolic heterogeneity of a murine model of TNBC (4T1 tumor line) and normal mammary tissues that have distinctly different metabolic pathways. Mammary tissues relied primarily on oxidative metabolism and showed high levels of glucose and fatty acid uptake across the entire imaging area reflecting a single metabolic phenotype. Though tumors were predominantly glycolytic, they displayed a heterogeneous distribution of nutrient preferences with regions dominated by either fatty acid uptake, glucose uptake, or both. Taken together, this work highlights the importance of not only capturing multiple metabolic endpoints but also investigating their spatial relationships to understand heterogeneity in key substrates and metabolic pathways for energy production in vivo.

  • Ignite: Place-based Community-centered Design to Promote Biomedical Engineering Efficacy

    by Jennifer Ayres, Hannah Lee, Amaris Huang, David Knudsen, Nirmala Ramanujam, Megan Madonna

  • Open Access

    In vivo spectroscopy to concurrently characterize five metabolic and vascular endpoints relevant to aggressive breast cancer

    by Victoria W. D’aGostino, Riley J. Deutsch, Michelle Kwan, Enakshi D. Sunassee, Megan C. Madonna, Gregory M. Palmer, Brian T. Crouch, Nirmala Ramanujam

    SignificanceEmerging evidence that aggressive breast tumors rely on various substrates including lipids and glucose to proliferate and recur necessitates the development of tools to track multiple metabolic and vascular endpoints concurrently in vivo.AimOur quantitative spectroscopy technique provides time-matched measurements of the three major axes of breast cancer metabolism as well as tissue vascular properties in vivo.ApproachWe leverage exogenous fluorophores to quantify oxidative phosphorylation, glucose uptake, and fatty acid oxidation, and endogenous contrast for measurements of hemoglobin and oxygen saturation. An inverse Monte Carlo algorithm corrects for aberrations resulting from tissue optical properties, allowing the unmixing of spectrally overlapping fluorophores.ResultsImplementation of our inverse Monte Carlo resulted in a linear relationship of fluorophore intensity with concentration (R2<0.99) in tissue-mimicking phantom validation studies. We next sequenced fluorophore delivery to faithfully recapitulate independent measurement of each fluorophore. The ratio of Bodipy FL C16/2-NBDG administered to a single animal is not different from that in paired animals receiving individual fluorophores (p=n.s.). Clustering of five variables was effective in distinguishing tumor from mammary tissue (sensitivity = 0.75, specificity = 0.83, and accuracy = 0.79).ConclusionsOur system can measure major axes of metabolism and associated vascular endpoints, allowing for future study of tumor metabolic flexibility.


  • Open Access

    Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence

    by Enakshi D. Sunassee, Riley J. Deutsch, Victoria W. D’aGostino, Pol Castellano-Escuder, Elizabeth A. Siebeneck, Olga Ilkayeva, Brian T. Crouch, Megan C. Madonna, Jeffrey Everitt, James V. Alvarez, et al.

    Fewer than 20% of triple-negative breast cancer patients experience long-term responses to mainstay chemotherapy. Resistant tumor subpopulations use alternative metabolic pathways to escape therapy, survive, and eventually recur. Here, we show in vivo, longitudinal metabolic reprogramming in residual disease and recurrence of triple-negative breast cancer xenografts with varying sensitivities to the chemotherapeutic drug paclitaxel. Optical imaging coupled with metabolomics reported an increase in non–glucose–driven mitochondrial metabolism and an increase in intratumoral metabolic heterogeneity during regression and residual disease in resistant MDA-MB-231 tumors. Conversely, sensitive HCC-1806 tumors were primarily reliant on glucose uptake and minimal changes in metabolism or heterogeneity were observed over the tumors’ therapeutic life cycles. Further, day-matched resistant HCC-1806 tumors revealed a higher reliance on mitochondrial metabolism and elevated metabolic heterogeneity compared to sensitive HCC-1806 tumors. Together, metabolic flexibility, increased reliance on mitochondrial metabolism, and increased metabolic heterogeneity are defining characteristics of persistent residual disease, features that will inform the appropriate type and timing of therapies.


  • Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC)

    by Enakshi D. Sunassee, Bruna Victorasso Jardim-Perassi, Megan C. Madonna, Bryce Ordway, Nirmala Ramanujam

    After an initial response to chemotherapy, tumor relapse is frequent. This event is reflective of both the spatiotemporal heterogeneities of the tumor microenvironment as well as the evolutionary propensity of cancer cell populations to adapt to variable conditions. Because the cause of this adaptation could be genetic or epigenetic, studying phenotypic properties such as tumor metabolism is useful as it reflects molecular, cellular, and tissue-level dynamics. In triple-negative breast cancer (TNBC), the characteristic metabolic phenotype is a highly fermentative state. However, during treatment, the spatial and temporal dynamics of the metabolic landscape are highly unstable, with surviving populations taking on a variety of metabolic states. Thus, longitudinally imaging tumor metabolism provides a promising approach to inform therapeutic strategies, and to monitor treatment responses to understand and mitigate recurrence. Here we summarize some examples of the metabolic plasticity reported in TNBC following chemotherapy and review the current metabolic imaging techniques available in monitoring chemotherapy responses clinically and preclinically. The ensemble of imaging technologies we describe has distinct attributes that make them uniquely suited for a particular length scale, biological model, and/or features that can be captured. We focus on TNBC to highlight the potential of each of these technological advances in understanding evolution-based therapeutic resistance.


  • Open Access

    In vivo metabolic imaging identifies lipid vulnerability in a preclinical model of Her2+/Neu breast cancer residual disease and recurrence

    by Megan C. Madonna, Joy E. Duer, Brock J. McKinney, Enakshi D. Sunassee, Brian T. Crouch, Olga Ilkayeva, Matthew D. Hirschey, James V. Alvarez, Nirmala Ramanujam

    Recurrent cancer cells that evade therapy is a leading cause of death in breast cancer patients. This risk is high for women showing an overexpression of human epidermal growth factor receptor 2 (Her2). Cells that persist can rely on different substrates for energy production relative to their primary tumor counterpart. Here, we characterize metabolic reprogramming related to tumor dormancy and recurrence in a doxycycline-induced Her2+/Neu model of breast cancer with varying times to recurrence using longitudinal fluorescence microscopy. Glucose uptake (2-NBDG) and mitochondrial membrane potential (TMRE) imaging metabolically phenotype mammary tumors as they transition to regression, dormancy, and recurrence. “Fast-recurrence” tumors (time to recurrence ~55 days), transition from glycolysis to mitochondrial metabolism during regression and this persists upon recurrence. “Slow-recurrence” tumors (time to recurrence ~100 days) rely on both glycolysis and mitochondrial metabolism during recurrence. The increase in mitochondrial activity in fast-recurrence tumors is attributed to a switch from glucose to fatty acids as the primary energy source for mitochondrial metabolism. Consequently, when fast-recurrence tumors receive treatment with a fatty acid inhibitor, Etomoxir, tumors report an increase in glucose uptake and lipid synthesis during regression. Treatment with Etomoxir ultimately prolongs survival. We show that metabolic reprogramming reports on tumor recurrence characteristics, particularly at time points that are essential for actionable targets. The temporal characteristics of metabolic reprogramming will be critical in determining the use of an appropriate timing for potential therapies; namely, the notion that metabolic-targeted inhibition during regression reports long-term therapeutic benefit.


  • Open Access

    A Spectroscopic Technique to Simultaneously Characterize Fatty Acid Uptake, Mitochondrial Activity, Vascularity, and Oxygen Saturation for Longitudinal Studies In Vivo

    by Riley J. Deutsch, Victoria W. D’agostino, Enakshi D. Sunassee, Michelle Kwan, Megan C. Madonna, Gregory Palmer, Brian T. Crouch, Nimmi Ramanujam

    Aggressive breast cancer has been shown to shift its metabolism towards increased lipid catabolism as the primary carbon source for oxidative phosphorylation. In this study, we present a technique to longitudinally monitor lipid metabolism and oxidative phosphorylation in pre-clinical tumor models to investigate the metabolic changes with mammary tissue development and characterize metabolic differences between primary murine breast cancer and normal mammary tissue. We used optical spectroscopy to measure the signal of two simultaneously injected exogenous fluorescent metabolic reporters: TMRE (oxidative phosphorylation surrogate) and Bodipy FL C16 (lipid catabolism surrogate). We leverage an inverse Monte Carlo algorithm to correct for aberrations resulting from tissue optical properties and to extract vascular endpoints relevant to oxidative metabolism, specifically oxygen saturation (SO2) and hemoglobin concentration ([Hb]). We extensively validated our optical method to demonstrate that our two fluorescent metabolic endpoints can be measured without chemical or optical crosstalk and that dual measurements of both fluorophores in vivo faithfully recapitulate the measurements of each fluorophore independently. We then applied our method to track the metabolism of growing 4T1 and 67NR breast tumors and aging mammary tissue, all highly metabolic tissue types. Our results show the changes in metabolism as a function of mammary age and tumor growth, and these changes can be best distinguished through the combination of endpoints measured with our system. Clustering analysis incorporating both Bodipy FL C16 and TMRE endpoints combined with either SO2 or [Hb] proved to be the most effective in minimizing intra-group variance and maximizing inter-group differences. Our platform can be extended to applications in which long-term metabolic flexibility is important to study, for example in tumor regression, recurrence following dormancy, and responses to cancer treatment.